Home > Joachim Burman, EAN 2019 – Non-myeloablative hematopoietic stem cell transplant in MS: MIST trial
Multiple Sclerosis

Joachim Burman, EAN 2019 – Non-myeloablative hematopoietic stem cell transplant in MS: MIST trial

Published Online: July 8th 2019

Joachim Burman (Uppsala University, Sweden) explains to us the rationale for the use of autologous non-myeloablative hematopoietic stem cell transplant (autoHSCT) in patients with relapsing remitting multiple sclerosis, and shares his insight on the MIST (Multiple Sclerosis International Stem cell Transplant) study findings.

Questions
1. What is the rationale for the use of autologous non-myeloablative hematopoietic stem cell transplant (autoHSCT) in patients with relapsing remitting multiple sclerosis? (0:04)
2. Could you tell us a little about the MIST (Multiple Sclerosis International Stem cell Transplant) study and its findings? (0:40)
3. What are the risks of this treatment? (1:44)
4. Which patients are most likely to respond to autoHSCT? (2:43)
5. What were the limitations of the MIST study and what further studies are planned? (3:11)

Speaker disclosure: Joachim Burman has nothing to disclose in relation to this video interview.

Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.

Share this Video
Related Videos In Multiple Sclerosis
Multiple Sclerosis
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis

It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]

Multiple Sclerosis
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials

It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]

Multiple Sclerosis
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials

It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]

Trending In Multiple Sclerosis:

Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
Multiple Sclerosis
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72